UK - GlaxoSmithKline is facing its second successive showdown with pension fund investors at its annual general meeting later this month.
The pharmaceutical giant was rocked last year when pension schemes joined a majority of disgruntled shareholders in rejecting the remuneration report. Now GSK is on a collision course over its l...
To continue reading this article...
Join Professional Pensions
Become a Professional Pensions Lite Member today
In just a few clicks you can start your free Professional Pensions Lite membership for 12 months, providing you access to:
- Three complimentary articles per month covering the latest real-time news, analysis and opinion from the industry
- Receive important and breaking news stories via our two daily news alerts
- Hear from industry experts and other forward-thinking leaders
Are you a trustee, investment consultant or in-house pension and benefit scheme professional? You can apply for full complimentary access here
